The GSK Value Offer

The Value of Vaccines

AWA

/GE

N/0001/14

2

With the Patient’s

best interest in

mind

Classic Brands

Vaccines

Branded Generics

Through Our Broad Portfolio of Products

We support you in providing the best value for the patient

Vaccines: the story so far

“With the exception of safe water, no other modality, not even antibiotics, has had such a major effect on mortality reduction...”

Plotkin S et al,Vaccines, 20111

Vaccines

Every year up to 3 million deaths are prevented and 750,000 children are saved from disabilities through vaccination2

What vaccination can achieve

• Globally:• Approximately 700,000 deaths caused by

pneumococcal disease could be prevented by 20158

• Cases of polio are down by over 99% - from over 300,000 per year in 1988 to less than 2,000 in 20099

• Some countries have witnessed declines in hospitalisations due to rotavirus infection of up to 80%10

• Vaccination and screening can bring down the burden of cervical cancer 11

• GlaxoSmithKline has vaccines in all these disease areas

• For over 50 years we have supplied polio vaccines for elimination and eradication efforts worldwide20

• Our pneumococcal conjugate vaccine (PCV) Synflorix™i was the first PCV to receive WHO ‘prequalification’ for global use

• RotarixTM has been included in government vaccination programmes for newborn babies in many countries.. Worldwide more than 100 million doses of RotarixTM have been distributed globally, the vast majority to Least Developed Countries20

i. SynflorixTM is a registered trade mark of the GlaxoSmithKline group of companies

ii. RotarixTM is a registered trade mark of the GlaxoSmithKline group of companies

GSK playing its part

Providing access to GSK vaccines

• In 2010, we delivered 1.4 billion vaccines doses to 179 countries worldwide19

•Up to 70% of our volumes are distributed in low and middle income countries19

•GSK has a tiered pricing policy to enable pricing to be aligned to a country’s ability to pay19

•The price for UN’s Least Developed Countries list should not exceed 25%* of the western European average21

* In very isolated cases existing contractual agreements with supranational organisations such as PAHO or GAVI may mean a higher figure than 25%

OUR COLLECTIVE CHALLENGE

“A vaccine that sitson the shelfis useless”

- Albert Sabin

Beyond The Antigen Support

Cold Chain Support Access & Advocacy

Patient information Leaflets/Videos

Disease AwarenessMaterials

Vaccination RecordCards

Capacity Building

House of Vaccines

GSK’s Support Beyond The Antigen

– Based on previous experience, GSK provides support to facilitate an effective vaccination experience:– Cold chain management– Social mobilization / Overcoming barriers to

vaccination– Vaccinator training

– GSK’ vast implementation knowledge ensures to make the most of a vaccine introduction program– Community– Hospital

• Decades of experience in vaccine introduction

• Localized & “bottom-up”: Relying on local knowledge

• Learnings from other countries and vaccines are leveraged

• On-going implementation monitoring and clinical surveillance

Value of holistic support

13

Childhood Vaccination Cards - New

14

15

DISEASE AWARENESS POSTERS

MENCEVAX ACWY

Hepatitis B

Hepatitis A

Measles, Mumps & Rubella

Chicken Pox

Meningococcal Meningitis

Rotavirus Gastroenteritis

Cervical Cancer

GSK HOUSE OF VACCINES – Protecting. Human. Kind

Invasive Pneumococcal Disease, Pneumonia & Otitis Media

Chicken Pox, Measles, Mumps & Rubella

Meningococcal Meningitis

Thank you

Why vaccinate against cervical cancer using Cervarix

Relying on the right choice

Cervical Cancer Vaccination Value Offer

Worldwide cervical cancer kills one

woman every two minutes1

Cervarix is dedicated to prevent Cervical Cancer

Cervarix from GSK offers values beyond the antigen

Cervical cancer is the second biggest cause of female cancer mortality

worldwide2

References:1. Ferlay J et al. Globocan 2002. IARC 20042. WHO initiative for vaccine research3. TBC

Persistent HPV infection is the necessary cause of Cervical Cancer

• All Women are at Risk of Oncogenic HPV throughout their Lives

Cervarix is dedicated to prevent Cervical

Cancer

High efficacy: ~100% for 16/18 and93% across all types

Lehtinen et al. Lancet Oncol 2012;13:89-99

Cervarix has a good safety and tolerability

profile

Cervarix – the appropriate choice for Cervical Cancer Protection

Cervarix has been licensed with a 2 dose schedule for girls 9-14

years

Cervarix from GSK offers values beyond the antigen

Efficacy of HPV vaccines

Overall vaccine efficacy

Efficacy against HPV 16/18

Efficacy against non-vaccine

oncogenic types

= +

Efficacy of HPV vaccines

Overall vaccine efficacy

Efficacy against HPV 16/18

Efficacy against non-vaccine

oncogenic types

= +

PATRICIA: Efficacy results against high grade lesions associated with HPV 16/18

1. Lehtinen M, et al. Lancet Oncol 2012; 13:89–99; 2. Paavonen J, et al. Lancet 2009; 374:301–314..

Endpoint Group N n Vaccine efficacy, %(95% CI)

CIN2+ Vaccine 5,466 1

99.0 (94.2–100.0)Control 5,452 97

CIN3+ Vaccine 5,466 0

100.0 (85.5–100.0)Control 5,452 27

TVC-naïve cohort

End-of-study analysis1

Approximateto young women before

sexual debut: ≥ 1 dose

Efficacy beyond HPV types 16 and 18

AWA/CER/0003/14

Efficacy of HPV vaccines

Overall vaccine efficacy

Efficacy against HPV 16/18

Efficacy against non-vaccine

oncogenic types

= +

– Estimated worldwide prevalence of HPV 16/18 in high-grade lesions (CIN2/3) is 51%2

TVC-naïve

1 Lehtinen M, et al. Lancet Oncol. 2012 Jan;13(1):89-99; 2. WHO/ICO Information Centre on Human papilloma Virus (HPV) and Cervical Cancer. Available at: http:www..hpvcentre.net/dataquery (accessed Jan 2014) ;

EndpointVaccine

casesN = 5,466

Control cases

N = 5,452

Efficacy, % 95% CI

CIN2+ irrespective of DNA in the lesion † 61 172 64.9 52.7–74.2

CIN3+ irrespective of DNA in the lesion 3 44 93.2 78.9–98.7

End of study analysis1

Approximateto young women before

sexual debut: ≥ 1 dose

PATRICIA: Efficacy results against high grade lesions irrespective of HPV type

DOSAGE

– AGED 9 – 14 YEARS OLD

– If flexibility in schedule is necessary, the 2nd dose can be given between 5 and 12 months after the 1st dose. If the 2nd dose is given before month 5, then a 3rd dose must be given.

– AGED15 YEARS AND OLDER

DOSE 1 DOSE 2

0 month 1 2 3 4 5 6 months

DOSE 1 DOSE 2 DOSE 3

0 month 1 month 2 3 4 5 6 months

If flexibility in schedule is necessary, the 2nd dose can be given between 1 and 2.5 monthsafter the 1st dose, and the 3rd dose between 5 and 12 months after the 1st dose.1

Cervarix. Summary of Product Characteristics. January 2014AWA/CER/0003/14

AWA

/CE

R/0003/14

Cervarix® Vaccine Pooled Studies: Safety Analysis

Descamps D, et al. Hum Vaccin 2009; 5:1–9.

SAE = severe adverse event.

Pooled clinical trial data analysis

(29,953 girls and women 10 to 72 years)

The most common adverse reaction was injection site pain: the majority were mild to moderate severity and were not long lasting

Fatigue, headache and myalgia were the most common solicited general symptoms

No significant increase in relative risk of potential autoimmune events detected in meta-analysis

Similar overall rates of pregnancy outcomes

AWA

/CE

R/0003/14

Further information

– Full Prescribing Information For Cervarix® Vaccine Is Available Upon Request

– For Safety Information Or For Reporting Any Adverse Event

Associated With GSK Products,

Kindly Call GSK 24-hours Dedicated Toll Free Line

0800CALLGSK (08002255475 )

THANK YOU

THANK YOU